The American Journal of Medicine
Volume 103, Issue 6 , Pages 462-467 , December 1997

Upper Gastrointestinal Adverse Events and Cyclical Etidronate

  • Tjeerd van Staa MD

      Affiliations

    • Procter & Gamble Pharmaceuticals, Lovett House, Lovett Road, Staines, United Kingdom
    • ,
  • Lucien Abenhaim MD

      Affiliations

    • Department of Epidemiology and Biostatistics, McGill University Montreal, Canada
    • Center for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada
    • Corresponding Author InformationL Abenhaim, MD, Center for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis-Jewish General Hospital, 3755, chemin de la Co̊te-Ste-Catherine, Montreal, Canada H3T 1E2.
    • ,
  • Cyrus Cooper MD

      Affiliations

    • Medical Research Council Environmental Epidemiology Unit, Southampton University Hospital, Southampton, United Kingdom

Received 14 January 1997 ,Accepted 21 May 1997.

References 

  1. Adami S, Zamberlan N. Adverse effects of bisphosphonates. Drug Safety. 1996;14:158–170
  2. Papapoulos SE. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In:  Marcus R,  Feldman D,  Kelsey J editor. Osteoporosis. San Diego: Academic Press; 1996;p. 419–434
  3. Abdelmalek MF, Douglas DD. Alendronate-induced ulcerative esophagitis. Am J Gastroenterol. 1996;91:1282–1283 Letter.
  4. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol. 1995;90:1889–1890
  5. de Groen PC, Lubbe DF, Hirsh LJ, et al.  Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016–1021
  6. Naylor G, Davies MH. Esophageal stricture associated with alendronic acid. Lancet. 1996;348:1030–1031 Letter.
  7. Sorrentino D, Trevisi A, Bernardis V, et al. Esophageal ulceration due to alendronate. Endoscopy. 1996;28:529. Letter.
  8. Nightingale ST. From the Food and Drug Administration. JAMA. 1996;275:1453
  9. Committee on Safety of Medicines, Medicines Control Agency . Current Problems in Pharmacovigilance. 1996;22:5
  10. Hall G. Pharmacoepidemiology using a UK Database of Primary Care Records. Pharmacoepidemiol Drug Saf. 1992;1:33–37
  11. Lis Y, Mann RD. The Vamp research multi-purpose database in the U.K.. J Clin Epidemiol. 1995;48:431–443
  12. Mann RD, Hall G, Chukwujindu J. Research implications of computerized primary care. Post Marketing Surveillance. 1992;5:259–268
  13. Hollowell J. General Practice Research Database (GPRD): Scope and Quality of Data. London: Office of Population Censuses and Statistics; 1994;
  14. Anonymous . The General Practice Research Database: Information for Researchers. London: Office for National Statistics; 1996;
  15. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302:766–768
  16. Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf. 1992;1:347–349
  17. Nazareth I, King M, Haines A, et al.  Accuracy of diagnosis of psychosis on general practice computer system. BMJ. 1993;307:32–34
  18. van Staa TP, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf. 1994;3:15–21
  19. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769–772
  20. van Staa TP, Abenhaim L, Leufkens H. A study of the effects of misclassification due to the time-window design in pharmacoepidemiologic studies. J Clin Epidemiol. 1994;47:183–189
  21. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods.. New York: Van Norstrand Reinhold Company Inc; 1982;
  22. Rothman KJ. Modern Epidemiology. Boston: Little, Brown and Company; 1986;
  23. Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon: International Agency for Research on Cancer; 1987;
  24. Kramer MS. Clinical Epidemiology and Biostatistics: A Primer For Clinical Investigators and Decision Makers. Berlin: Springer-Verlag; 1988;
  25. Heaney RP. How do we know what we know? The randomized controlled trial revisited. J Bone Miner Res. 1991;6:103–105
  26. Heaney RP. How can we tell if a treatment works? Further thoughts on the randomized controlled trial. Osteoporosis Int. 1991;1:215–217
  27. Kramer MS, Shapiro SH. Scientific challenges in the application of randomized trials. JAMA. 1984;252:2739–2745
  28. British National Formulary Number 32 (September 1996) . British Medical Association and the Royal Pharmaceutical Society of Great Britain. Wallingford, England: Pharmaceutical Press; 1996;
  29. Geddes AD, D’Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structure-activity relationships and therapeutic implications. In:  Heersche JNM,  Kanis JA editor. Bone and Mineral Research. 8:Elsevier Science; 1994;p. 265–306

☆ This work was supported by Procter & Gamble Pharmaceuticals.

PII: S0002-9343(97)00242-8

The American Journal of Medicine
Volume 103, Issue 6 , Pages 462-467 , December 1997

Article Tools

* Image Usage & Resolution